4521
Kaken Pharmaceutical Co., Ltd.
2026/02/06
For the third quarter of the fiscal year ending March 2026, net sales amounted to 57,617 million yen (24.2% decrease year-over-year), operating income was 554 million yen (97.8% decrease year-over-year), and net income attributable to owners of parent was 1,398 million yen (92.7% decrease year-over-year).
